Qartemi Launches India's First Approved CAR-T Therapy to Treat B-NHL Patients

As India's first international CAR-T therapy, Qartemi received approval to treat adult B-cell Non-Hodgkin Lymphoma (B-NHL). The new treatment system helps blood cancer patients find better health results especially those who failed previous standard therapies. Doctors use CAR-T therapy to improve patient T-cell function by reprogramming blood cells so they target and destroy cancer cells better. This method turns T-cells into active cancer treatments that can remain inside a patient's body to fight their disease after the latest infusion,it is also known as a living drug.

The process typically involves:

1. Collecting T-cells from the patient.

2. Genetically modifying the cells to express receptors that target cancer cells.

3. Reinfusing the modified T-cells back into the patient's body to eliminate the cancer

Clinical Trials and Efficacy

• The research team at Narayana Hospital and Apollo Cancer Hospital tested CAR-T Therapy through IMAGINE trial.

• During Phase 2 trials modified T-cells achieved 83.3% effectiveness against cancer target cells.

• The treatment proves successful when it needs to fight back against cancer that has returned or refuses to go away in patients with B-NHL.

Impact of Blood Cancer in India

• Each year India observes 120,000 new cases of people developing blood cancers.

• Patients with aggressive B-NHL now have a fresh medical treatment option thanks to Qartemi.

• Bone marrow transplants may become less necessary as this therapy option becomes available.

Future of Cancer Treatment

Qartemi launches represent significant progress toward personalized medicine treatment in India. Through advanced research and local manufacturing methods. Qartemi prepares to reshape cancer therapy in India. This new treatment option will transform blood cancer care and create possibilities for creating specialized cancer medicines across India.

What is Non-Hodgkin Lymphoma (NHL) as a form of cancer?

The body's immune system immune system starts non-Hodgkin lymphoma cancer develop there. The lymphatic system consists of glands organs vessels and lymph nodes across the body to fight infections. When NHL occurs the B-cells of the lymphatic system reproduce beyond control resulting in tumors throughout the body. NHL is a broad category of lymphomas, with many different subtypes, including:

• Diffuse Large B-cell Lymphoma is the main type of non-Hodgkin's Lymphoma.

• Follicular Lymphoma

NHL requires unique medical handling from Hodgkin Lymphoma and has different ways to diagnose and treat this condition.

Conclusion

Qartemi marks a leap forward in how India treats patients with B-cell Non-Hodgkin Lymphoma (B-NHL). India advances its cancer treatment technology by welcoming CAR-T therapy which benefits patients with severe blood cancers. The discovery provides comfort to patients and prepares India to deliver better cancer treatment.